| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6176939 | European Urology | 2014 | 7 Pages |
Abstract
We looked at the antitumour activity of the chemotherapy drug cabazitaxel in men previously treated with docetaxel chemotherapy and the hormonal drugs abiraterone and enzalutamide. Cabazitaxel appeared active when given after abiraterone and enzalutamide. We can reassure men that cabazitaxel can be used after these novel endocrine treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Carmel J. Pezaro, Aurelius G. Omlin, Amelia Altavilla, David Lorente, Roberta Ferraldeschi, Diletta Bianchini, David Dearnaley, Christopher Parker, Johann S. de Bono, Gerhardt Attard,